PMID- 33607496
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1879-0372 (Electronic)
IS  - 0952-7915 (Linking)
VI  - 70
DP  - 2021 Jun
TI  - Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon 
      receptor signaling.
PG  - 33-39
LID - S0952-7915(21)00005-4 [pii]
LID - 10.1016/j.coi.2021.02.003 [doi]
AB  - Dendritic cells (DCs) are potent antigen-presenting cells (APCs), which sample 
      the exogenous and endogenous cues to control adaptive immunity, balancing 
      effector and regulatory components of the immune response. Multiple subsets of 
      DCs, such as plasmacytoid and conventional DCs, have been defined based on 
      specific phenotypic markers, functions and regulatory transcriptional programs. 
      Tolerogenic DCs (tolDCs) have been functionally defined based on their ability to 
      expand the regulatory T-cell compartment and suppress immune responses. However, 
      it is still unclear whether tolDCs represent a homogeneous population, a specific 
      DC subset and/or a heterogeneous collection of DC activation/maturation states. 
      The ligand-activated transcription factor aryl hydrocarbon receptor (AHR) has 
      been shown to control transcriptional programs associated to tolDCs. In this 
      review, we discuss the role of AHR in the control of tolDCs, and also 
      AHR-targeted approaches for the therapeutic induction of tolDCs in autoimmune 
      diseases and allergy.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Barroso, Andreia
AU  - Barroso A
AD  - Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard 
      Medical School, Boston, MA, USA.
FAU - Mahler, Joao V
AU  - Mahler JV
AD  - Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard 
      Medical School, Boston, MA, USA; Faculdade de Medicina FMUSP, Universidade de Sao 
      Paulo, Sao Paulo, SP, Brazil.
FAU - Fonseca-Castro, Pedro H
AU  - Fonseca-Castro PH
AD  - Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard 
      Medical School, Boston, MA, USA; Faculdade de Medicina FMUSP, Universidade de Sao 
      Paulo, Sao Paulo, SP, Brazil.
FAU - Quintana, Francisco J
AU  - Quintana FJ
AD  - Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard 
      Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, 
      MA, USA. Electronic address: fquintana@rics.bwh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210216
PL  - England
TA  - Curr Opin Immunol
JT  - Current opinion in immunology
JID - 8900118
RN  - 0 (AHR protein, human)
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (Receptors, Aryl Hydrocarbon)
SB  - IM
MH  - Autoimmune Diseases/immunology
MH  - Basic Helix-Loop-Helix Transcription Factors/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Hypersensitivity/immunology
MH  - Receptors, Aryl Hydrocarbon/*immunology
MH  - Signal Transduction/immunology
EDAT- 2021/02/20 06:00
MHDA- 2022/01/18 06:00
CRDT- 2021/02/19 20:15
PHST- 2020/11/24 00:00 [received]
PHST- 2021/01/28 00:00 [revised]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/02/20 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/02/19 20:15 [entrez]
AID - S0952-7915(21)00005-4 [pii]
AID - 10.1016/j.coi.2021.02.003 [doi]
PST - ppublish
SO  - Curr Opin Immunol. 2021 Jun;70:33-39. doi: 10.1016/j.coi.2021.02.003. Epub 2021 
      Feb 16.